


 SEP 07 2001

## SEQUENCE LISTING

&lt;110&gt; Efendic, Suad

&lt;120&gt; USE OF GLP-1 OR ANALOGS IN TREATMENT OF MYOCARDIAL INFARCTION

&lt;130&gt; X-10822A

&lt;140&gt; US 09/834,229

&lt;141&gt; 2001-04-12

&lt;150&gt; US 08/915,918

&lt;151&gt; 1997-08-21

&lt;150&gt; US 06/024,980

&lt;151&gt; 1996-08-30

&lt;160&gt; 6

&lt;170&gt; PatentIn version 3.1

&lt;210&gt; 1

&lt;211&gt; 31

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 1

His Ala Glu Gly Thr Phe Thr Ser Asp Val Ser Ser Tyr Leu Glu Gly  
 1 5 10 15

Gln Ala Ala Lys Glu Phe Ile Ala Trp Leu Val Lys Gly Arg Gly  
 20 25 30

&lt;210&gt; 2

&lt;211&gt; 31

&lt;212&gt; PRT

&lt;213&gt; Artificial Sequence

&lt;220&gt;

&lt;223&gt; synthetic construct

&lt;220&gt;

&lt;221&gt; MISC\_FEATURE

&lt;222&gt; (1)..(1)

<223> Xaa at position 1 is L-histidine, D-histidine, desamino-histidine  
 , 2-amino-histidine, B-hydroxy-histidine, homohistidine, alpha-fl  
 uoromethyl-histidine, and aplpha-methyl-histidine;

&lt;220&gt;

&lt;221&gt; MISC\_FEATURE

&lt;222&gt; (2)..(2)

<223> Xaa at position 2 is Ala, Gly, Val, Thr, Ile, and alpha-methyl-Al  
 a;

&lt;220&gt;

&lt;221&gt; MISC\_FEATURE

&lt;222&gt; (15)..(15)

<223> Xaa at position 15 is Glu, Gln, Ala, Thr, Ser, and Gly;

<220>  
 <221> MISC\_FEATURE  
 <222> (21)..(21)  
 <223> Xaa at position 21 is Glu, Gln, Ala, Thr, Ser, and Gly;

<220>  
 <221> MOD\_RES  
 <222> (31)..(31)  
 <223> AMIDATION

<220>  
 <221> MISC\_FEATURE  
 <222> (31)..(31)  
 <223> Xaa at position 31 is Gly

<400> 2

Xaa Xaa Glu Gly Thr Phe Thr Ser Asp Val Ser Ser Tyr Leu Xaa Gly  
 1 5 10 15

Gln Ala Ala Lys Xaa Phe Ile Ala Trp Leu Val Lys Gly Arg Xaa  
 20 25 30

<210> 3  
 <211> 29  
 <212> PRT  
 <213> Artificial Sequence

<220>  
 <223> synthetic construct

<220>  
 <221> MISC\_FEATURE  
 <222> (29)..(29)  
 <223> Xaa at position 29 is absent or Gly.

<400> 3

His Ala Glu Gly Thr Phe Thr Ser Asp Val Ser Ser Tyr Leu Glu Gly  
 1 5 10 15

Gln Ala Ala Lys Glu Phe Ile Ala Trp Leu Val Lys Xaa  
 20 25

<210> 4  
 <211> 30  
 <212> PRT  
 <213> Artificial Sequence

<220>  
 <223> synthetic construct

<220>  
 <221> MISC\_FEATURE  
 <222> (19)..(19)

<223> Xaa at position 19 is Lys or Arg;

<220>

<221> MOD\_RES

<222> (30)..(30)

<223> AMIDATION

<220>

<221> MISC\_FEATURE

<222> (30)..(30)

<223> Xaa at position 30 is Gly.

<400> 4

Ala Glu Gly Thr Phe Thr Ser Asp Val Ser Ser Tyr Leu Glu Gly Gln  
1 5 10 15

Ala Ala Xaa Glu Phe Ile Ala Trp Leu Val Lys Gly Arg Xaa  
20 25 30

<210> 5

<211> 30

<212> PRT

<213> Artificial Sequence

<220>

<223> synthetic construct

<400> 5

His Ala Glu Gly Thr Phe Thr Ser Asp Val Ser Ser Tyr Leu Glu Gly  
1 5 10 15

Gln Ala Ala Lys Glu Phe Ile Ala Trp Leu Val Lys Gly Arg  
20 25 30

<210> 6

<211> 4

<212> PRT

<213> Artificial Sequence

<220>

<223> synthetic construct

<400> 6

Ser Arg Arg Gln  
1